Released Nov 5, 2019, after the close
10-Q filed Nov 8, 2019, 39 days after period end · 0001162194-19-000088
Q3 2019 · 10-Q
Revenue$26.50M$26.50M −8.5% vs Q3 2018−6.0% vs Q2 2019
Net Income-$12.89M-$12.89M N/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.19-$0.19 N/M vs Q3 2018N/M vs Q2 2019
Gross Profit$13,838,000−12.5%
Operating Income-$13,816,000N/M
Operating Cash Flowderived-$4,548,000N/M
Free Cash Flowderived-$5,894,000N/M
Margins · derived
Gross margin52.2%−2.4 pt vs Q3 2018
Operating margin-52.1%−12.0 pt vs Q3 2018
Net margin-48.6%+2.3 pt vs Q3 2018
What the release said
The release
Same quarter
| Metric | Q3 2019 | Q3 2018 | Q3 2017 | Q3 2016 |
|---|---|---|---|---|
| Revenue | $26.50M | $28.96M | $24.75M | $22.19M |
| Net Income | -$12.89M | -$14.75M | -$15.94M | -$19.79M |
| EPS Diluted | -$0.19 | -$0.38 | -$0.46 | -$0.68 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR